Aerie COO: Expanding innovation of glaucoma therapeutics

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Related Content:

ConferencesGlaucomaTechnology

Analyzing real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

Aerie reports positive phase 3 results for netarsudil 0.02% vs ripasudil 0.4% in lowering IOP

Intravitreal pegcetacoplan for GA: Phase 3 results of OAKS and DERBY studies